Special ELSI Club Episode: Going beyond diagnostic yield: GENEPOD

More and more patients have the opportunity to receive secondary findings as a result of genetic tests, and while guidelines prioritize those that are medically actionable, patients could also receive secondary findings related to results that are currently considered non-actionable, such as monogenic disease risk and pharmacogenomic variants. There are questions about what the large volume of information could mean for both patients and for clinical care, and whether the results are useful to the patient and their clinicians. A team of researchers recently conducted a study on the topic; the resulting paper is called, “Opportunistic genomic screening has clinical utility: an interventional cohort study.” It was also the subject of discussion at the journal club convened by the Center for ELSI Resources and Analysis, a collaboration and dissemination hub focused on the ethical, legal, and social implications of genetics and genomics.